OpenCitations metadata only

Rituximab Chimeric anti-CD20 Monoclonal Antibody Therapy For Relapsed Indolent Lymphoma: Half Of Patients Respond To A Four-Dose Treatment Program.

McLaughlin, P [omid:ra/061808009298]; Grillo-López, A J [omid:ra/061808009299]; Link, Brian K. [orcid:0000-0001-5084-0698 omid:ra/0613010803182]; Levy, R [omid:ra/061808009300]; Czuczman, M S [omid:ra/061808009301]; Williams, M E [omid:ra/061808009302]; Heyman, M R [omid:ra/061808009303]; Bence-Bruckler, I [omid:ra/061808009304]; White, C A [omid:ra/061808009305]; Cabanillas, F [omid:ra/061808009306]; Jain, V [omid:ra/061808009307]; Ho, A D [omid:ra/061808009308]; Lister, J [omid:ra/061808009309]; Wey, K [omid:ra/061808009310]; Shen, D [omid:ra/061808009311]; Dallaire, B K [omid:ra/061808009312]

OpenCitations · Papers

Open Source ↗

citations doi seed

Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

Explore in Search →Connect via MCP / API ↗

This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗

Rituximab Chimeric anti-CD20 Monoclonal Antibody Therapy For Relapsed Indolent Lymphoma: Half Of Patients Respond To A Four-Dose Treatment Program.

Analyze & explore related research in Conceptio

Related documents